Videos

Close Video

SPHR.L6.13GBp-0.25 (-3.92%)

52wk Low / High
5.09 / 14.79
Market Cap
£8.68m
Shares in Issue
141.76m
Earnings Per Share (TTM)
-
Current PE Ratio (TTM)
-
Div / Yield
- / -

Quotes delayed, except where indicated otherwise. Currency in GBp.

Overview

Sphere Medical Holding plc (AIM:SPHR) is a medical devices company, providing monitoring and diagnostic devices for the critical care setting. Sphere’s flagship device Proxima is a patient-dedicated blood gas analysis solution for use in monitoring patients who are critically ill. It is typically used in the Intensive Care Unit and Operating Room and is highly differentiated, as blood is drawn from the patient over the sensor, but then returned to the patient.

The nurse can take a measurement without having to leave the patient’s bedside. The closed system has a number of benefits – in particular it conserves blood, reducing the possibility of hospital acquired anaemia and potentially the need for transfusions; the closed system also reduces the infection risk.

The first commercial version, Proxima 3, has been launched and achieved first sales. Proxima 4, which adds glucose monitoring to the existing panel, is applicable to around four times as many patients as Proxima 3; making it significantly more attractive to partners. Sphere remains on track for CE mark in 2016, with launch into Sphere’s direct markets (UK, Germany, Netherlands and Belgium) shortly afterwards.

www.spheremedical.com

Directors

Dr David Martyr (NE Chair)
CEO of Tecan AG, a Swiss listed laboratory instruments company valued at >CHF 1BN.

Dr Wolfgang Rencken (CEO)
Responsible for development & launch of many innovative medical devices. Previously CEO MAQUET Cardiopulmonary AG & COO Definiens AG.

Richard Wright (CFO)
20 yrs in financial roles. Previously 8yrs as FD Alliance Pharma plc.

John Gregory (Snr Ind Dir & NED)
NE Chair of Foresight VCT plc & NED or Chair of a number of private companies. Former Dir Singer & Friedlander Holdings.

NED’s
Stephen H Mahle (former VP Medtronic Inc.), Meinhard Schmidt (held snr positions at Roche), Brenig Priest (20 yrs in finance & healthcare)

Financials

P&L2015
£~000
2014
£~000
Gross Revenue
15
14
Operating Expenses(6,126)(5,945)
Loss for the period(5,465)(5,347)
Balance Sheet2015
£~000
2014
£~000
Cash & Equivalents10,028
3,703
Total Assets11.538
4,242

Peer Group

Deltex (AIM: DEMG)
manufactures & markets haemodynamic monitoring technologies.

LiDCO (AIM: LID)
hemodynamic monitoring

Lombard Medical inc (NASDAQ: EVAR)
treatment of abdominal aortic aneurysms

Shareholders

Directors
Wolfgang Rencken – 0.32%
Stephen Mahle – 0.11%
Meinhard Schmidt – 0.13%
Dr David Martyr – 0.09%

Other
Woodford – 28%
Arthurian Life Sciences – 17.64%
LSP Advisory – 7.69%
Johnson & Johnson – 5.74%
Octopus Investments – 4.41%

Macro Indicators

“The blood-gas and electrolyte analyser market was estimated at $3.2billion in 2014 and is growing about 4% per annum; driven by an increase in the number of critical care patients and measurement of a wider range of analytes.” (Panmure Gordon note, Feb 2016)

“The expected increase in population over the age of 65 would require a 52% rise in ICU beds to cope with demand. (Coke et al., Critical Care and Resuscitation, 2009).

Media Coverage

Business Weekly (Feb 2016)

“Sphere Medical Holdings, has managed to keep a steady hand on finances despite accelerating the commercialisation of its lead product, Proxima 3 and preparing for the launch of its nextgen solution.”

Broker Coverage

Panmure Gordon (Feb 2016 – House Broker)
“We believe the appointment of a distribution partner will substantially increase the share price, as in addition to validating the technology, it should provide access to a much wider range of customers, in new hospitals across different geographies enabling a faster growth rate.”

Trinity Delta (Feb 2016)
“Various generations of Proxima have been produced, with Proxima 3 being the first version to market (UK in 2014). However, it is the latest generation, Proxima 4, with added functionalities, that is expected to gain commercial traction.”

Submit your details to be kept up to date with announcements regarding Sphere Medical Holdings Plc

We have a strict data protection policy and will not share your details with external parties.